Study #2024-0208
Phase I/II study of AD-PluReceptor plus Tafasitamab-cxix and Lymphodepleting chemotherapy in patients with autoimmune disorders
MD Anderson Study Status
Enrolling
Treatment Agent
Tafasitamab, Fludarabine phosphate, Cyclophosphamide
Description
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Autoimmune Disorders, Systemic Sclerosis
Study phase:
Physician name:
Chitra Hosing
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-327-0346
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.